Welcome to our dedicated page for IMV news (Ticker: IMV), a resource for investors and traders seeking the latest updates and insights on IMV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMV's position in the market.
IMV Inc. has announced its financial results for 2020, highlighting significant progress in its immunotherapy pipeline, especially Maveropepimut-S. With cash reserves of $46.4 million, the company aims to advance its clinical programs, including two Phase 2 trials and exploratory studies in multiple solid tumors. IMV reported a net loss of $34.9 million, attributed to increased research and administrative expenses. The company is poised for 2021 with multiple milestones, including FDA engagement and new clinical trials for its promising DPX-based therapies.
IMV Inc. will hold a conference call and webcast on March 17, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. Participants can join by calling (866) 211-3204 (U.S. & Canada) or (647) 689-6600 (international) with conference ID: 8998652. The webcast will also be accessible live via the company’s website. IMV is focused on advancing immunotherapy, particularly its lead candidate, DPX-Survivac, for ovarian cancer, along with a COVID-19 vaccine development.
IMV announced its executive management team's participation in the H.C. Wainwright Global Life Sciences Conference, taking place virtually on March 9-10, 2021. The presentation is scheduled for March 9 at 7:00 AM ET and will be available for 30 days on IMV’s website. The company is pioneering cancer immunotherapies and vaccines, with a focus on its lead candidate, DPX-Survivac, which targets survivin. IMV highlights potential FDA accelerated approval and the ongoing clinical studies for its therapies.
IMV, a clinical-stage biopharmaceutical company, announced participation in two virtual investor events. The BTIG Fireside Chat is scheduled for January 7, 2021, at 12:15 PM ET. The H.C. Wainwright Fireside Chat (Bioconnect 2021 Conference) will occur on January 11, 2021, starting at 6:00 AM ET and will be available on demand for a week. Webcasts of these events can be found in the investors section of IMV’s website. The press release notes that forward-looking statements are made regarding FDA approvals and ongoing trials with the potential for varied outcomes.
IMV Inc. (Nasdaq: IMV) announced an update on its DPX-COVID-19 vaccine candidate aimed at preventing COVID-19. The company has completed safety studies confirming a favorable profile and long-lasting antibody response. Preliminary results show promise for protection against SARS-CoV-2 variants, as targeted areas of the vaccine are less prone to mutations. IMV received Cdn $10M in non-dilutive funding and is collaborating with manufacturing partners to produce hundreds of millions of doses globally. Further preclinical studies and updates are expected in Q1 2021.